Dyskeratosis Congenita Fibroblasts Are Abnormal and Have Unbalanced Chromosomal Rearrangements

By Inderjeet Dolak, Julie Bungey, Peter Williamson, David Oscier, Jill Hows, and Lucio Luzzatto

Dyskeratosis congenita (DC) is a rare inherited disorder characterized by bone marrow failure, dystrophic changes in the skin and mucous membranes, and a predisposition to malignancy. The DC locus has been mapped to Xq28. The primary defect responsible for this disease remains unknown. We have studied four patients with this disease, three from one family and one from another. In all four patients, primary skin fibroblast cultures were abnormal both in morphology (polygonal cell shape, ballooning, and dendritic-like projections) and in growth rate (doubling time about twice normal). Fibroblast survival studies using four clastogens (bleomycin, diepoxybutane, mitomycin-c, and 4-nitroquinoline-1-oxide) and gamma radiation showed no significant difference between DC and normal fibroblasts. Cytogenetic studies performed on peripheral blood lymphocytes showed no difference between DC and normal lymphocytes with or without prior incubation with clastogens. However, bone marrow metaphases from one of three patients and fibroblasts from two of four patients (who were the eldest of the 4) showed numerous unbalanced chromosomal rearrangements (dicentrics, tricentrics, and translocations) in the absence of any clastogenic agents. Cell-specific differences and a higher rate of chromosomal rearrangements in the older patients appear to correlate with the clinical evolution of the disease. These findings suggest that the DC defect predisposes DC cells to developing chromosomal rearrangements.

Address reprint requests to Lucio Luzzatto, MD, Department of Haematology, Royal Postgraduate Medical School and Hammersmith Hospital, 150 Du Cane Rd, London W12 ONN, UK.

I.D. was supported by the Medical Research Council.

From the Department of Haematology, Royal Postgraduate Medical School and Hammersmith Hospital, London, and the Department of Haematology, Royal Victoria Hospital, Bournemouth, UK.

Submitted May 11, 1992; accepted August 17, 1992.

J.D. was supported by the Medical Research Council.

Address reprint requests to Lucio Luzzatto, MD, Department of Haematology, Royal Postgraduate Medical School and Hammersmith Hospital, 150 Du Cane Rd, London W12 ONN, UK.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1992 by The American Society of Hematology.

Fibroblast morphology.
(A) Fibroblasts from a normal control (original magnification ×400). (B) Fibroblasts from a patient with DC (original magnification ×400) showing abnormal morphology (polygonal shape, ballooning, and dendritic-like projections).

Cytogenetic studies on peripheral blood (PB) lymphocytes were performed with and without prior exposure to clastogens.

RFLP Genetic Linkage Study
An RFLP genetic linkage study was undertaken in family A using the DXS52(St14-1) probe and Taq I digestion as described by Connor et al.

Patients
Family A
Patient 1. Patient 1 (the index case in family A) first presented at the age of 29 years in August 1989 with symptoms of anemia. He was found to have oral leukoplakia, nail dystrophy, and skin pigmentation. Investigations showed he had severe pancytopenia (hemoglobin [Hb], 3.2 g/dL; white blood cell count [WBC], 1.2 × 10^9/L; platelets, 6 × 10^9/L). A biopsy of the BM showed that it was very hypocellular, with approximately 10% myeloblasts. In January 1990, he was referred to the Hammersmith Hospital for matched unrelated donor (MUD) BMT, at which time his HLA-identical younger brother (patient 2) was also diagnosed to have DC. Because the fibroblast survival studies had shown that his cells were not hypersensitive to clastogens, he was conditioned with the same dose (50 mg/kg × 4) of cyclophosphamide as that used for patients with acquired aplastic anemia rather than the low dose (5 mg/kg × 4) used in FA and total body irradiation. He did not develop severe mucosal toxicity, but failed to engraft. As a salvage
because of a deterioration in his blood count (WBC, 2 x 10^9/L). He was assessed as a potential BM donor for his elder brother (patient 1). Like his brother, he had nail dystrophy, skin pigmentation, and oral leukoplakia. He was asymptomatic with a normal PB count. However, his BM culture studies showed a significant reduction in hematopoietic progenitors: CFU-GM were 5.0 per 10^5 mononuclear cells plated (normal range, 40 to 240); burst-forming units-erythroid (BFU-E) were 4.5 per 10^5 mononuclear cells plated (normal range, 30 to 330).

**Family B**

**Patient 4.** Patient 4 was referred to the Hammersmith Hospital at the age of 15 years in May 1990 for consideration for MUD BMT because of a deterioration in his blood count (WBC, 2 x 10^9/L; platelets, 30 x 10^9/L). His BM cultures showed a significant reduction in hematopoietic progenitors: CFU-GM were 5.0 per 10^5 mononuclear cells plated; BFU-E were 7.5 per 10^5 mononuclear cells plated. Similar to the three patients in family A, he had nail dystrophy, leukoplakia, and skin pigmentation. In addition, he also had an esophageal stricture, partial deafness, hypogonadism, and mild mental retardation. No suitable MUD donor was found and he died in July 1991.

**RESULTS**

**Fibroblast Morphology**

In all four patients, primary skin fibroblasts were abnormal in morphology (polyonal cell shape, ballooning, and dendritic-like projections; Fig 1A and B). The different fibroblast cultures were of similar ages because the skin biopsies from which they were established were all taken simultaneously. The growth rate was also abnormal for all DC fibroblasts. The doubling time for normal fibroblasts was 2 to 3 days, whereas for DC fibroblasts it was 6 to 10 days. In one obligate carrier (the mother of patients 1 and 2), the fibroblasts looked normal and the doubling time was 2 days (ie, indistinguishable from normal).

**Sensitivity to Clastogenic Agents**

Fibroblast survival studies using bleomycin (0 to 120 μg/mL for 2 hours), diepoxybutane (0 to 10 μg/mL for 1 hour), mitomycin-c (0 to 25 nmol/L continuously administered), 4-nitroquinoline-1-oxide (0 to 25 nmol/L continuously administered), and gamma radiation (0 to 250 rad as a pulse) showed no significant difference between DC and normal fibroblasts (Fig 2). This is in sharp contrast to FA fibroblasts, which, as expected, were hypersensitive to diepoxybutane (Fig 2A) and mitomycin-c (Fig 2B).

**Cytogenetic Analyses**

**PB**

PB lymphocytes showed no difference (gaps or breaks) between DC and normal lymphocytes with or without prior incubation with diepoxybutane (0.1 μg/mL for 48 hours), mitomycin-c (5 μg/mL for 72 hours), or 4-nitroquinoline-1-oxide (10^-5 mol/L for 48 hours). This is in sharp contrast to cells from patients with FA, which show increased chromosomal gaps and breaks upon exposure to clastogens.

In one of four patients (the eldest of the 4), a triradial configuration (Fig 3A) was seen in 1 of 30 metaphases without prior exposure to clastogens.

![Fig 2](https://www.bloodjournal.org) - Sensitivity to clastogen agents. (A) Diepoxybutane survival curves showing no difference in sensitivity between DC and normal fibroblasts. The Fanconi fibroblast line (Ch Ru) is hypersensitive to diepoxybutane compared with normal fibroblasts. (B) Mitomycin-c survival curves showing no difference in sensitivity between DC and normal fibroblasts. The Fanconi fibroblast line (GM6914) is hypersensitive to mitomycin-c compared with normal fibroblasts.
BM

BM from one of three patients (the eldest of the 4) showed (Fig 3B) numerous unbalanced chromosomal rearrangements without prior incubation with any clastogens.

Fibroblasts

Fibroblasts from two of four patients (the 2 eldest patients) showed a variety of unbalanced chromosomal rearrangements (dicentrics, tricentrics, and translocations) in the absence of any clastogens. Fibroblasts from the other two patients showed no chromosomal rearrangements. The type of abnormalities seen in the two patients (patients 1 and 2) are shown in Fig 3C and listed in Table 1. In addition, inversion 8 [inv(8)(p11.2q22)] was seen in all the metaphases from patient 2. This abnormality was also observed in his mother and, therefore, we believe it is unrelated to DC.

RFLP Linkage Analysis

A linkage study was undertaken in family A because the two sisters of patients 1 and 2 wished to know whether they were carriers of the DC allele. Because Connor et al9 have shown no recombination between the DC gene and the RFLPs identified by St14-1 in nine informative meiotic events (maximal Lod score of 3.33 at zero recombination

Fig 3. Cytogenetic abnormalities. (A) Metaphase spread made from PB of the eldest patient (patient 1) showing a triradial configuration. (B) Metaphase spread made from the BM of patient 1 showing a ring chromosome.
Fig 3. (Cont’d) (C) Partial karyotype showing chromosomal rearrangements identified in fibroblast culture from patient 1. Two types of dicentric chromosomes and one tricentric resulting from rearrangements between chromosomes 9 and 12 are shown.

PB lymphocytes from all DC patients (and obligate carriers) did not exhibit increased chromosomal breakage with or without prior incubation with clastogens. In addition, fibroblasts from all four patients were not hypersensitive to bleomycin, diepoxynbutane, mitomycin-c, 4-nitroquinoline-1-oxide, and gamma radiation. This confirms the findings of some previous studies. However, some studies have shown increased sensitivity of DC cells to ionising radiation or to 4-nitroquinoline-1-oxide and bleomycin. These discordant findings regarding the response of DC cells to clastogens and radiation may result from genetic heterogeneity in the disease. Therefore, in a given patient it is impossible to predict the sensitivity to clastogens and whether a patient is to receive high-dose chemoradiotherapy before a BMT. It is important to establish the sensitivity of that individual's cells to clastogens to ensure that the appropriate dose of chemotherapy is administered. In patient 1, the fibroblast survival studies and the lymphocyte cytogenetic studies had shown normal sensitivity to clastogens. He was therefore treated with the same dose of cyclophosphamide as that used for patients with acquired aplastic anemia rather than low-dose cyclophosphamide used in FA patients. This patient did not develop severe mucosal sensitivity posttransplant and, despite high-dose cyclophosphamide, rejected the first graft.

### DISCUSSION

PB lymphocytes from all DC patients (and obligate carriers) did not exhibit increased chromosomal breakage with or without prior incubation with clastogens. In addition, fibroblasts from all four patients were not hypersensitive to bleomycin, diepoxynbutane, mitomycin-c, 4-nitroquinoline-1-oxide, and gamma radiation. This confirms the findings of some previous studies. However, some studies have shown increased sensitivity of DC cells to ionising radiation or to 4-nitroquinoline-1-oxide and bleomycin. These discordant findings regarding the response of DC cells to clastogens and radiation may result from genetic heterogeneity in the disease. Therefore, in a given patient it is impossible to predict the sensitivity to clastogens and whether a patient is to receive high-dose chemoradiotherapy before a BMT. It is important to establish the sensitivity of that individual's cells to clastogens to ensure that the appropriate dose of chemotherapy is administered. In patient 1, the fibroblast survival studies and the lymphocyte cytogenetic studies had shown normal sensitivity to clastogens. He was therefore treated with the same dose of cyclophosphamide as that used for patients with acquired aplastic anemia rather than low-dose cyclophosphamide used in FA patients. This patient did not develop severe mucosal sensitivity posttransplant and, despite high-dose cyclophosphamide, rejected the first graft.

### Table 1. Chromosomal Rearrangements Seen in Patients 1 and 2 in the Absence of Clastogens

<table>
<thead>
<tr>
<th>Metaphases Examined</th>
<th>PB</th>
<th>BM</th>
<th>Fibroblasts</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>12</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>1 triradial</td>
<td>5 46,XY, der(22) t (1:22)</td>
<td>1 dicentric (9;12)</td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>46,XY</td>
<td>2 46,XY, -18, + R</td>
<td>1 dicentric (9;12), 12p+</td>
</tr>
<tr>
<td></td>
<td>5 46,XY</td>
<td></td>
<td>12p+</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 dicentric (12;22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 isochromosome (12q), 9q+</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 dicentric (12;7;12), 9q+, 9q+</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 Robertsonian translocation (14;15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 tricentric isochromosome (12;9;9;12) + isochromosome (9p)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 translocation (9;12), 12p+, Robertsonian translocation (22;22)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1 46,XY</td>
</tr>
<tr>
<td>Patient 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>15</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>46,XY</td>
<td>4 inversion 8*</td>
<td></td>
</tr>
<tr>
<td>inversion 8*</td>
<td>inversion 8*</td>
<td>4 inversion 8*, translocation 3;12</td>
<td></td>
</tr>
<tr>
<td>Inversion 8*</td>
<td>inversion 8*</td>
<td>2 inversion 8*, der(11) t (1;11)</td>
<td></td>
</tr>
</tbody>
</table>

Inversion 8* [inv(8)(p11.2q22)] was seen in all metaphases from patient 2. This was also observed in the patient’s mother, and we therefore infer that it is constitutional and unrelated to DC.

Abbreviation: R, ring chromosome.
DC FIBROBLASTS ARE ABNORMAL

Fig 4. Pedigree of family A. The RFLP analysis for the individuals studied using the St14-1 probe and Taq I digestion are indicated. (▲) Female carriers; (■) male affected members. The index case in this family is indicated by the arrow. He was found to have inherited the 4.5-kb fragment from his mother. The disease was therefore segregating with this 4.5-kb fragment. This RFLP analysis was informative up to generation V and allowed us to identify female carriers and one individual (patient 3) with DC before he had presented with clinical abnormalities. Because the mother of the boy (age 2 years at time of analysis) in generation V was homozygous for the 4.5-kb fragment, it was not possible to say whether this boy had DC.

suggesting the presence of residual, functional host lymphocytes after therapy. In this case, therefore, the in vitro studies correlated well with the in vivo observation.

Fibroblasts from all four patients were abnormal in both morphology and growth rate. Furthermore, fibroblasts from two of the four patients (the 2 older patients) showed numerous unbalanced chromosomal rearrangements in the absence of any clastogens. The elder of these two patients (patient 1) also had similar chromosomal abnormalities (but less numerous) in the blood and BM, with morphologic evidence for leukemic transformation. The demonstration of unbalanced chromosomal rearrangements in the PB, BM, and fibroblasts in the oldest patient and in the fibroblasts alone in the second oldest patient suggests a primary defect that predisposes DC cells to developing chromosomal rearrangements. These findings of cell-specific differences and of a high rate of chromosomal rearrangements in the two older patients appears to correlate with the evolution of the disease in vivo.

In our linkage study, we found that the fragments identified by the St14-1 probe after Taq I digestion of genomic DNA were informative and allowed us to correctly identify carriers and patient 3 in family A. Thus, this study confirms the findings of Connor et al6 and strengthens the linkage between the DC locus and the RFLPs identified by St14-1. Furthermore, this RFLP linkage analysis clearly shows that, in family A, DC is segregating as an X-linked recessive trait.

Although patients with FA and DC share some features in common (eg, BM aplasia), they appear to differ in two fundamental ways. Firstly, unlike Fanconi cells, in our four patients, DC cells were not hypersensitive to clastogens. Secondly, the primary defect in DC appears to predispose cells to developing chromosomal rearrangements rather than the chromosomal gaps and breaks seen in FA.

ACKNOWLEDGMENT

We are very grateful to M. Fitchett and Dr M. Crocker for performing extensive cytogenetic work on two of the patients.

REFERENCES

Dyskeratosis congenita fibroblasts are abnormal and have unbalanced chromosomal rearrangements

I Dokal, J Bungey, P Williamson, D Oscier, J Hows and L Luzzatto